Evidence map›Paper›PMID 37199752›Full record

ReviewApplied microbiology and biotechnology2023

Production of recombinant scorpion antivenoms in E. coli: current state and perspectives.

Susana María Alonso Villela, Hazar Kraïem-Ghezal, Balkiss Bouhaouala-Zahar, Carine Bideaux, César Arturo Aceves Lara, Luc Fillaudeau

Abstract readReview
PubMed Publisher
In one paragraph

Review in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Molecular Mechanisms of Animal Toxins, Venoms and Antivenoms.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Susana María Alonso VillelaTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France. salonsovillela@gmail.com.ORCID http://orcid.org/0000-0001-8290-1635
Hazar Kraïem-GhezalLaboratoire Des Venins Et Molécules Thérapeutiques, Institut Pasteur de Tunis, Université de Tunis El Manar, 13 Place Pasteur BP74, 1002, Tunis, Tunisia.ORCID http://orcid.org/0000-0002-8180-0573
Balkiss Bouhaouala-ZaharLaboratoire Des Venins Et Molécules Thérapeutiques, Institut Pasteur de Tunis, Université de Tunis El Manar, 13 Place Pasteur BP74, 1002, Tunis, Tunisia. balkiss.bouhaouala@fmt.utm.tn.ORCID http://orcid.org/0000-0003-3147-245X
Carine BideauxTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.ORCID http://orcid.org/0000-0002-9830-5093
César Arturo Aceves LaraTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.ORCID http://orcid.org/0000-0001-6291-3655
Luc FillaudeauTBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.ORCID http://orcid.org/0000-0002-6389-5441
Centre National de la Recherche Scientifique · FRTunis University · TN

Funding

Consejo Nacional de Ciencia y Tecnología 461347
6 · The paper itself

Abstract

Scorpion envenomation is a serious health problem in tropical and subtropical zones. The access to scorpion antivenom is sometimes limited in availability and specificity. The classical production process is cumbersome, from the hyper-immunization of the horses to the IgG digestion and purification of the F(ab)'

Indexed as

Scorpion VenomsSingle-Chain AntibodiesSingle-Domain AntibodiesAnimalsAntiveninsEscherichia coliHorsesHumansRecombinant ProteinsScorpionsAntiveninsRecombinant ProteinsScorpion VenomsSingle-Chain AntibodiesSingle-Domain AntibodiesAntibody fragmentsButhidae scorpionsRecombinant proteinScorpion antivenom

Identifiers

PMID37199752
OpenAlexW4377011233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.